External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
NCT ID: NCT07082478
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5 participants
OBSERVATIONAL
2025-07-28
2026-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study has two phases. This is the first phase, and the purpose is to test comfort and feasibility of a novel in-ear wearable device (Lumia Health) that measures blood flow changes to the head. Information from the study will help the investigators determine if the device is suitable to be used in the second phase of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanisms of Post-Bariatric Hypoglycemia
NCT04428866
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
NCT06986603
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
NCT02733588
Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 1
NCT05212207
Glycemic Patterns After Bariatric Surgery and High Glycemic Variability and Hypoglycemia Unawareness Risk Factors
NCT05728320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the screening visit, a study team member will go over the informed consent form with participants and will explain why this study is being done and the study procedures involved. Participants will have to sign the consent form before any study related procedures take place. After participants sign the consent, the following procedures will be done to ensure eligibility and that it is safe to be part of the study.
* Review medical history by the study doctor.
* Participants will be asked to sign a release of information form so that the investigators may obtain additional information about medical history from prior physicians and hospitals. Medical records including laboratory results (within the last 6 months) will be reviewed by the study doctor.
* Physical examination, vital signs and anthropometrics (blood pressure, heart rate, temperature, height and weight) and an otoscopic exam (a look inside the external ear).
* Urine pregnancy test (if participant is a female of child bearing potential) that must be negative in order to continue participation.
* Questionnaires: Investigators will ask participants to fill out several questionnaires that will help the investigators assess any symptoms of low blood sugar or autonomic symptoms:
* Edinburgh Hypoglycemia Symptom Scale (EHSS)
* Dumping Symptom Rating Scale (DSRS) questionnaire
* Composite Autonomic Symptom Score (COMPASS 31)
* Orthostatic Hypotension Questionnaire (OHQ)
* Devices: If the participant is eligible, a member of the study team will place the following devices. The participant will wear both devices for 10 days (24 hours per day) · Lumia Health: A small in-ear wearable device will be placed to monitor the blood flow to the head. The study team will make sure it fits comfortably and show the participant how to use it properly. A member of the Lumia team may be present during the placement of the device in order to assist the study team with choosing the best size of the device to match the shape of the participant's ear. If the participant is uncomfortable with this, study team members will be able to perform this procedure (after receiving instructions from a Lumia team member).
Procedure: (1) Removing earrings or jewelry if needed and cleaning the outer ear to ensure a secure fit. (2) Positioning the device on the frontal surface of the left ear cartilage. (3) Adjusting it to fit comfortably. If participant experiences any discomfort during placement, they will be asked to inform the study team.
Employees at Lumia Health will process signals from the device and provide the Joslin team with the blood flow information. This information will be de-identified, meaning it will not include any personally identifiable data.
Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin on the abdomen to monitor the participant's sensor glucose (sugar) levels.
Insertion Procedure: (1) A suitable location on the abdomen is identified. (2) The CGM is placed against the skin at the chosen site. The sensor is inserted in the skin with a simple press or click; this causes little to no discomfort. (3) A small transmitter is connected to the sensor to allow glucose readings to be transmitted to a monitoring device (receiver), which the participant will keep with them during the duration of the monitoring period.
Diaries: Investigators will ask participants to keep a written paper diary of daily meals, liquids (including caffeinated beverages), physical activity and any issues with the device (Lumia).
At the end of the visit, the participant will be scheduled for the next 2 visits. Additionally, the participant will be provided contact information for the study team in case any questions or issues arise during the study.
Visit 2 (Follow up)
This visit will happen remotely, between days 4-6 after Visit 1. A study team member will call the participant by video or phone. This visit will include:
Wellness check: The investigators will check how the participant is doing, see if there are any problems, and ask about experience with both the ear and CGM devices.
Ear device check: A member of the study team will review the data collected on the cloud from previous days to ensure the ear device is functioning properly. If everything is working well, the investigators will encourage participants to continue wearing the device . If there are issues with data collection or problems with device, the investigators will provide instructions to improve data collection and schedule a follow-up call if needed.
Questions and support: Investigators will be available to answer any questions that the participant may have.
At the end of this call visit, the investigators will provide instructions for the next visit.
Visit 3 (End of Study)
This visit will last approximately 2 hours at the Joslin Diabetes Center. The visit will include the following:
Review medical history, including any updates since the last visit. Physical examination, vital signs (blood pressure, heart rate, temperature, height and weight) and an otoscopic exam (a look inside the external ear).
Review of diaries the participant completed during the study. The participant will be asked to complete the same surveys as at Visit 1 and additional surveys about the experience with the device.
The participant will return study devices to the study team so the information can be downloaded for analysis.
The investigator will review the glucose monitoring information with the participant at the end of this visit, but will not be able to review data from the ear device.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
healthy individuals
individuals with no history of hypoglycemia or upper gastrointestinal surgery
in-ear device measuring blood flow
A small in-ear wearable device will be placed to monitor the blood flow to the head. The investigators will make sure it fits comfortably and show the participant how to use it properly.
Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin of the abdomen to monitor sensor sugar levels.
These sensors will be placed during visit one and will be worn together for 10 days. A followup visit (visit 2) will occur remotely at 4-6 days later. A final visit will occur after 10 days when the device will be removed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
in-ear device measuring blood flow
A small in-ear wearable device will be placed to monitor the blood flow to the head. The investigators will make sure it fits comfortably and show the participant how to use it properly.
Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin of the abdomen to monitor sensor sugar levels.
These sensors will be placed during visit one and will be worn together for 10 days. A followup visit (visit 2) will occur remotely at 4-6 days later. A final visit will occur after 10 days when the device will be removed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals able to provide informed consent and follow all study procedures, including complete daily food, activity, and symptom diaries, and willingness to provide access to medical record review.
* For healthy control group: individuals without a history of upper gastrointestinal surgery and without reported symptoms of hypoglycemia.
* Individuals with access to personal iPhone running operating system 16 (iOS) or later versions (not feasible for Android platform users) and a password-protected home Wi-Fi network.
Exclusion Criteria
* History of myocardial infarction, unstable angina or revascularization within the past 6 months.
* History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia.
* Documented hypoglycemia occurring in the fasting state (\> 12 hours fast).
* Concurrent administration of β-blocker therapy.
* Vigorous physical activity within 24 hours prior to assessment.
* Seizure disorder (other than with suspect or documented hypoglycemia).
* Hematocrit \< 33% (women) or \<36% (men) within the past 6 months.
* History of insulinoma.
* Use of central nervous system-active medications, including: antidepressants, anxiolytics, antipsychotics, stimulants, antiepileptics, sedatives and opioids.
* History of severe neurologic vascular disease (e.g. cerebrovascular disease/stroke).
* History of previous diseases associated with dysautonomia (e.g. multiple system atrophy, multiple sclerosis, Parkinson's disease).
* Impaired hepatic function (aspartate amino transaminase and/or alanine amino transaminase \>2x upper limit of normal range), as determined within the past 6 months.
* Impaired renal function (serum creatinine \>1.5 mg/dL), as determined within the past 6 months.
* Serious psychiatric or substance abuse disorders (e.g. alcohol, opioid, cocaine use disorder), as judged by the study investigator.
* Non-consent or inability to comply with study procedures.
* Current pregnancy and/ or lactation.
* Vulnerable individuals (e.g., fetuses, children, prisoners) and those judged by the investigator to be unsuitable for the study.
* Individuals wearing earrings or other jewelry in the left ear who are unable or unwilling to remove them for the duration of the study.
* Unwillingness to wear study masked CGM for duration of study
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Joslin Diabetes Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary Elizabeth Patti
Senior Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary E Patti, M.D.
Role: PRINCIPAL_INVESTIGATOR
Joslin Diabetes Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joslin Diabetes Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994 Jul;17(7):697-703. doi: 10.2337/diacare.17.7.697.
Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.
Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012 Dec;87(12):1196-201. doi: 10.1016/j.mayocp.2012.10.013.
Laurenius A, Olbers T, Naslund I, Karlsson J. Dumping syndrome following gastric bypass: validation of the dumping symptom rating scale. Obes Surg. 2013 Jun;23(6):740-55. doi: 10.1007/s11695-012-0856-0.
Deary IJ, Hepburn DA, MacLeod KM, Frier BM. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia. 1993 Aug;36(8):771-7. doi: 10.1007/BF00401150.
Addison P, Carsky K, Patti ME, Roslin M. Hypoglycemia and Dysautonomia After Bariatric Surgery: a Systematic Review and Perspective. Obes Surg. 2022 May;32(5):1681-1688. doi: 10.1007/s11695-022-05960-x. Epub 2022 Feb 8.
Zhang JB, Tamboli RA, Albaugh VL, Williams DB, Kilkelly DM, Grijalva CG, Shibao CA. The incidence of orthostatic intolerance after bariatric surgery. Obes Sci Pract. 2019 Dec 6;6(1):76-83. doi: 10.1002/osp4.383. eCollection 2020 Feb.
Tripathi H, Gonuguntla A, Lee D, Fudim M, Brinker J, Tandri H. Monitoring Carotid Blood Flow Using In-Ear Wearable Device During Tilt-Table Testing. JACC Clin Electrophysiol. 2023 May;9(5):710-712. doi: 10.1016/j.jacep.2023.02.002. Epub 2023 Mar 22. No abstract available.
An Z, Wang H, Mokadem M. Role of the Autonomic Nervous System in Mechanism of Energy and Glucose Regulation Post Bariatric Surgery. Front Neurosci. 2021 Nov 23;15:770690. doi: 10.3389/fnins.2021.770690. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00000303
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.